Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AQXP

Aquinox Pharmaceuticals (AQXP) Stock Price, News & Analysis

Aquinox Pharmaceuticals logo

About Aquinox Pharmaceuticals Stock (NASDAQ:AQXP)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$11.02
$13.83
50-Day Range
$3.68
$4.03
52-Week Range
$2.00
$3.84
Volume
678,766 shs
Average Volume
239,362 shs
Market Capitalization
$275.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Remove Ads
Receive AQXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquinox Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AQXP Stock News Headlines

Mirum Pharmaceuticals, Inc. (MIRM)
Why Aquinox Pharma (AQXP) Stock Might be a Great Pick
New “Trump” currency proposed in DC
After a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out first. Warren Buffett sold off 115 million shares of Apple last year.
See More Headlines

AQXP Stock Analysis - Frequently Asked Questions

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) announced its earnings results on Thursday, November, 8th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.43.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aquinox Pharmaceuticals investors own include Novavax (NVAX), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), XOMA (XOMA), Alnylam Pharmaceuticals (ALNY) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/08/2018
Today
4/01/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AQXP
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-31,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$25 million
Price / Cash Flow
N/A
Book Value
$3.09 per share
Price / Book
3.79

Miscellaneous

Free Float
N/A
Market Cap
$275.65 million
Optionable
Not Optionable
Beta
-7.37
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:AQXP) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners